Search
Tractament antiviral de l'hepatitis C crònica a l'any 2019, 2020 i 2021: informe d'avaluació de resultats
(2022-02)
Minority diseases pose a major challenge to the health system, as they often have a genetic origin, can affect many organs, be serious, pose a vital threat, or be chronically debilitating. Their diagnosis is difficult, ...
Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics
(2020-07-07)
Neuroendocrine tumors (TNEs) are defined as those neoplasms with a predominantly neuroendocrine cell differentiation, which can arise in most organs, although most are of gastrointestinal or pancreatic origin (≈65%). The ...
Document informatiu dels fàrmacs d'acció lenta sobre els símptomes de l'artrosi (SYSADOA)
(2020-10-27)
Slow-acting drugs on the symptoms of osteoarthritis or SYSADOA (from the acronym in
English, SYmptomatic Slow Action Drugs for OsteoArthritis) are glucosamine (a
aminomonosaccharide, in the form of sulphate or ...
Tractament de malalties minoritàries amb medicaments d'autorització individual a l'any 2019: informe d'avaluació de resultats
(2020)
Minority diseases pose a major challenge to the health system, as they are often of genetic origin and can affect many organs, be serious, pose a threat to life, or be chronically debilitating. Their diagnosis is difficult, ...
Trastuzumab per al tractament del càncer gàstric o d'unió gastroesofàgica metàstasic HER2+: informe d'avaluació de resultats
(2018)
Trastuzumab is a humanized monoclonal antibody against human epidermal growth factor (HER2) receptor 2, which in 2010 was approved by the European Agency of the
Medication (EMA) for the treatment of gastric cancer or ...
Argumentari de les pautes per a l’harmonització del tractament farmacològic de la incontinència urinària
(2021-03-04)
The CatSalut Pharmacotherapeutic Harmonization Guidelines are a tool aimed at all healthcare professionals to establish good practices in the pharmacological management of different priority pathologies. Urinary incontinence ...
Tractament farmacològic de la malaltia d’Alzheimer: informe del Registre de Tractament Farmacològic de la Malaltia d’Alzheimer a l’any 2019
(2020)
Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disorder that is usually slow but sustained over time. AD is the most common cause of dementia (69%). Its prevalence is 5.1% and increases exponentially ...
Guanfacina: tractament del trastorn per dèficit d'atenció amb hiperactivitat (TDAH) en nens i adolescents de 6 a 17 anys quan els estimulants no són adequats, no es toleren o han mostrat ser ineficaços
(2017-10)
Attention Deficit Hyperactivity Disorder (ADHD) is a disorder of neurobiological origin that starts at the age of children and affects between 3% and 7% of school-age children. Race with three types of nonspecific symptoms: ...